Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Pulmonary Hypertension, Preterm Infant
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 0 Minutes to 45 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypertension
Interventions: Physical activity, Dietary, Primary care provider visit; Behavioral · Other
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Olympia, Washington

Conditions: Kidney, Polycystic
Interventions: Lisinopril, Telmisartan, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 15 Years to 64 Years
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more

Conditions: Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Interventions: iloprost Inhalation, iloprost; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Hypertension
Interventions: Baroreceptor Stimulation; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Glaucoma
Interventions: Ahmed FP7 Valve, Baerveldt-350 Tube; Device
Lead sponsor: Credit Valley EyeCare; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 3
States / cities: Indianapolis, Indiana • Nashville, Tennessee • Milwaukee, Wisconsin

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Interventions: Placebo, LAM-001; Drug
Lead sponsor: IRulya Therapeutics Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 4
States / cities: Tucson, Arizona • New Haven, Connecticut • Boston, Massachusetts + 1 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Tracleer®; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Sickle Cell Anemia, Pulmonary Hypertension
Interventions: Nitric Oxide, INO Pulse - NO Delivery System; Drug · Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C, Latanoprost 0.005% eye drops; Drug
Lead sponsor: ViSci Ltd.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bellevue, Washington

Conditions: Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour), Hypertension
Interventions: Losartan, Allopurinol, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Green Bay, Wisconsin • La Crosse, Wisconsin • Madison, Wisconsin + 1 more

Conditions: Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension
Interventions: HS135, Placebo; Biological · Other
Lead sponsor: 35Pharma Inc., a GSK company; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Phoenix, Arizona • Kansas City, Missouri

Conditions: Pregnancy Related, Obesity, Hypertension
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 120 participants
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension, Obesity
Interventions: Soft Commitment Device; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: Semi-structured, open ended interview; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Ocular Hypertension, Open-Angle Glaucoma
Interventions: Istalol and Optive, Alphagan; Drug
Lead sponsor: Bp Consulting, Inc; Network
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Petaluma, California

Conditions: Hypertension, Kidney Diseases
Interventions: Vitamin D3, Omega-3 Fatty acids, Vitamin D3 placebo, Fish oil placebo; Dietary Supplement · Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 50 Years to 99 Years
Enrollment: 2,232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Nebivolol, Metoprolol ER (TM); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension
Interventions: Aliskiren/HCTZ; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Respiratory Distress, Transient Tachypnea of the Newborn, Delayed Transition of the Newborn, Persistent Pulmonary Hypertension
Interventions: prone positioning, Supine; Procedure
Lead sponsor: Montefiore Medical Center; Other
Eligibility: Female only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: African Americans With Hypertension.
Interventions: 12-week lifestyle modification; Behavioral
Lead sponsor: Morehouse School of Medicine; Other
Eligibility: 21 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Resistant Hypertension, Hypercortisolism
Interventions: Not listed
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 50
States / cities: Huntington Park, California • La Jolla, California • Los Angeles, California + 42 more

Conditions: Albuminuria, Chronic Kidney Diseases, Diabetes, Hypertension
Interventions: Minuteful - Kidney Urine Analysis Test System; Device
Lead sponsor: Healthy.io Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Garden City, New York

Conditions: Hypertension
Interventions: Modified Sodium Watcher Program + Digital Self-Monitoring, Usual care + Digital Self-Monitoring; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 40 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Registry of Preterm Newborns With Severe Pulmonary Hypertension

Prevalence, Awareness and Management of Hypertension in Acute Care Personnel

HALT Progression of Polycystic Kidney Disease Study B

Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD)

Acute Carotid Sinus Endovascular Stimulation II Study

The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology

Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Study of Cardiovascular Disease and Obstructive Sleep Apnea

Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Monitoring Movement and Health Study

Intermittent Fasting Adherence and Self Tracking

Cornell Translational Behavioral Science Research Consortium: Hypertension Qualitative Study

Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)

Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives

A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients

A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients

Effect of Supine or Prone Position After Caesarean Birth

Metro Atlanta Heart Disease Study - II (MAHDS II)

Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)

Evaluation of the Accuracy and Usability of the Minuteful - Kidney Urine Analysis Test System in the Lay User Hands

Examining the Individual Response to a Restricted Sodium Diet in Hypertensive Patients